Search

Your search keyword '"Schena M."' showing total 16 results
Start Over Author "Schena M." Publisher elsevier bv
16 results on '"Schena M."'

2. Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”

Author

Novello, S., primary, Torri, V., additional, Grohe, C., additional, Kurz, S., additional, Serke, M., additional, Wehler, T., additional, Meyer, A., additional, Ladage, D., additional, Geissler, M., additional, Colantonio, I., additional, Cauchi, C., additional, Stoelben, E., additional, Ceribelli, A., additional, Kropf-Sanchen, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Gregorc, V., additional, Chiari, R., additional, Reck, M., additional, Schmid-Bindert, G., additional, Folprecht, G., additional, Griesinger, F., additional, Follador, A., additional, Pedrazzoli, P., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N.J., additional, Irtelli, L., additional, Wiest, G., additional, Monica, V., additional, Porcu, L., additional, Manegold, C., additional, and Scagliotti, G.V., additional

Published
2022
Full Text
View/download PDF

3. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

Author

Novello, S., primary, Torri, V., additional, Grohe, C., additional, Kurz, S., additional, Serke, M., additional, Wehler, T., additional, Meyer, A., additional, Ladage, D., additional, Geissler, M., additional, Colantonio, I., additional, Cauchi, C., additional, Stoelben, E., additional, Ceribelli, A., additional, Kropf-Sanchen, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Gregorc, V., additional, Chiari, R., additional, Reck, M., additional, Schmid-Bindert, G., additional, Folprecht, G., additional, Griesinger, F., additional, Follador, A., additional, Pedrazzoli, P., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N.J., additional, Irtelli, L., additional, Wiest, G., additional, Monica, V., additional, Porcu, L., additional, Manegold, C., additional, and Scagliotti, G.V., additional

Published
2022
Full Text
View/download PDF

4. PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

Author

Novello, S., primary, Monica, V., additional, Serke, M., additional, Grohe, C., additional, Meyer, A., additional, Geissler, M., additional, Colantonio, I., additional, Stoelben, E., additional, Cecere, F., additional, Schutte, W., additional, Schumann, C., additional, Valmadre, G., additional, Borra, G., additional, Schena, M., additional, Morabito, A., additional, Santo, A., additional, Chiari, R., additional, Gregorc, V., additional, Reck, M., additional, Manegold, C., additional, Griesinger, F., additional, Follador, A., additional, Ferrari, A., additional, Bearz, A., additional, Caffo, O., additional, Dickgreber, N., additional, Irtelli, L., additional, Wiest, G.h., additional, Sotoparra, H., additional, Spatafora, M., additional, Righi, L., additional, Torri, V., additional, Porcu, L., additional, Arizio, F., additional, and Scagliotti, G., additional

Published
2021
Full Text
View/download PDF

7. Parameters and outcomes in 525 patients operated on for oral squamous cell carcinoma

Author

Garzino-Demo, P., primary, Zavattero, E., additional, Franco, P., additional, Fasolis, M., additional, Tanteri, G., additional, Mettus, A., additional, Tosco, P., additional, Chiusa, L., additional, Airoldi, M., additional, Ostellino, O., additional, Schena, M., additional, Rampino, M., additional, Ricardi, U., additional, Evangelista, A., additional, Merletti, F., additional, Berrone, S., additional, and Ramieri, G., additional

Published
2016
Full Text
View/download PDF

8. Concomitant Adjuvant Chemoradiotherapy with Weekly Low-dose Cisplatin for High-risk Squamous Cell Carcinoma of the Head and Neck: a Phase II Prospective Trial

Author

Rampino, M., primary, Ricardi, U., additional, Munoz, F., additional, Reali, A., additional, Barone, C., additional, Musu, A.R., additional, Balcet, V., additional, Franco, P., additional, Grillo, R., additional, Bustreo, S., additional, Pecorari, G., additional, Cavalot, A., additional, Garzino Demo, P., additional, Ciuffreda, L., additional, Ragona, R., additional, and Schena, M., additional

Published
2011
Full Text
View/download PDF

16. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer

Author

Luca Conti, Luca Molinaro, Francesca Maletta, Eugenio Maiorano, Sofia Asioli, Cristina Botta, Carla Pecchioni, Giuseppe Ingravallo, Luigi Chiusa, Anna Sapino, Maria Antonietta Satolli, Giuseppe Viale, M. Schena, Ludovica Verdun di Cantogno, Asioli S, Maletta F, Verdun di Cantogno L, Satolli MA, Schena M, Pecchioni C, Botta C, Chiusa L, Molinaro L, Conti L, Viale G, Ingravallo G, Maiorano E, and Sapino A

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Receptor, ErbB-2, medicine.medical_treatment, In situ hybridization, Adenocarcinoma, HercepTest, Specimen Handling, Pathology and Forensic Medicine, Stomach Neoplasms, HER2, medicine, Biomarkers, Tumor, Humans, Gastric cancer, Immunohistochemistry, Surgical specimen, Aged, Aged, 80 and over, biology, Cancer, Reproducibility of Results, Middle Aged, medicine.disease, Prognosis, Primary tumor, Survival Rate, Tissue Array Analysis, Lymphatic Metastasis, biology.protein, Gastrectomy, Female, Lymph, Lymph Nodes, Antibody
Abstract

Summary Gastric cancer shows intratumoral heterogeneity for human epidermal growth factor receptor 2 expression. We evaluated whether the number of tissue blocks analyzed or the antibodies used may influence the immunohistochemical results in gastrectomy specimens. Clinicopathologic data from 148 patients receiving gastric surgery for cancer were collected. One tissue block for each of 88 primary tumors and 60 paired primary tumors and metastases was examined for human epidermal growth factor receptor 2 status by immunohistochemistry using 3 different antibodies (HercepTest, CB11, and 4B5) and by fluorescent in situ hybridization. Two additional tissue blocks of the primary tumor were tested by immunohistochemistry if the results were negative on the first tissue block. The concordance among the 3 antibodies was 94.5% (testing 1 tissue block). Two cases showed a clinically significant discrepancy between primary tumor (score 0) and lymph nodes metastases (score 3+). Additional block analysis increased both the sensitivity (from 63% to 83%) and the accuracy (from 91% to 94%) of immunohistochemistry as compared with fluorescent in situ hybridization. The multiblock approach could potentially identify a greater number of human epidermal growth factor receptor 2–positive gastric cancers, particularly those with higher levels of intratumor heterogeneity. In turn, human epidermal growth factor receptor 2 positivity correlated with a worse prognosis ( P = .011) and was an independent variable in multivariate analysis (hazard ratio, 1.57). In conclusion, testing more than 1 tissue block of cancer from specimens of gastric resection provides a more reliable human epidermal growth factor receptor 2 assessment regardless of the antibody used.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results